NEW YORK, Feb. 7-Oxford GlycoSciences has opened a new specialty biopharmaceutical headquarters in the United States, the company said today.
The new facility is located in Bridgewater, NJ.
It will be run by Don DeGolyer, Oxford GlycoSciences' new president of global therapeutics. DeGolyer will lead the company's research into specialty biopharmaceuticals, both in the US and internationally.
The New Jersey office will house the company's commercial team, lead by vice president of global marketing Lou Ferrari.
Oxford GlycoScience's drug development focuses on treatments for fungal infections, cancer, Gaucher disease and Fabry's disease.